This website is being reviewed for updates. Some information is offline. We apologize for any inconvenience.
Skip to main content
Rural Health Information Hub
Rural Health Information Hub

FDA: Revocation of Emergency Use of a Drug Product During the COVID-19 Pandemic; Availability

Source
Federal Register
Link
View Full Story
Date
Jul 29, 2025
Summary
The Food and Drug Administration (FDA) has revoked Emergency Use Authorizations issued to Regeneron Pharmaceuticals, Inc., for REGEN-COV (casirivimab and imdevimab administered together); GlaxoSmithKline LLC for sotrovimab; Eli Lilly and Company for bebtelovimab; and AstraZeneca Pharmaceuticals LP for EVUSHELD (tixagevimab co-packaged with cilgavimab). These revocations are effective December 13, 2024.
Tagged as
COVID-19 · Legislation and regulations · Pharmacy and prescription drugs